News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: New Data Analyses Show Consistent Efficacy And Safety Profile Of Pradaxa® In Broad Range Of Patients With Acute Deep Vein Thrombosis Or Pulmonary Embolism


12/10/2013 10:55:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only. New data analyses show that the positive treatment effect (efficacy and safety profile) of Pradaxa® (dabigatran etexilate) 150mg twice daily was consistent in a wide range of patients with acute deep vein thrombosis (DVT), a blood clot in the leg veins, or pulmonary embolism (PE), a blood clot in the lung, regardless of age, renal function, simultaneous use of non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (ASA), or the presence of cancer.1-4 These new findings from the pooled safety analysis of the RE-COVER™ and RE-COVER™ II phase III clinical trials were presented this week during the American Society of Hematology Annual Meeting, New Orleans, USA.1-4

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES